Duloxetine
Product Images NDC 70934-729

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 70934-729). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (70934 729 30 Master Bottle Label Approval Rev A 08 20)

Label for Duloxetine Delayed-Release Capsules, USP 30mg, by Denton Pharma, Inc. dba Northwind Pharmaceuticals. The label indicates a package count of 30 capsules for Rx use. It includes storage instructions, manufacturer details, and a lot number with expiration date fields.*

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure diagram of Duloxetine with annotation showing the hydrochloride (HCl) salt form. The structure includes a thiophene ring, naphthalene moiety, and methylated amine group as part of the molecule.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line graph comparing the proportion of patients with relapse over time between Duloxetine delayed-release capsules and placebo. The x-axis represents time from randomization to relapse in days, ranging from 0 to 250. The y-axis shows the proportion of patients with relapse from 0.0 to 1.0. The graph includes two lines: a solid line for Duloxetine delayed-release capsules and a dashed line for placebo, illustrating lower relapse proportion over time for Duloxetine.*

FDA Label Image

Figure 2 (Duloxetine 03)

A Kaplan-Meier curve graph depicting the proportion of patients with relapse over time (days) after randomization. The graph compares two treatments: placebo (dashed line) and duloxetine delayed-release capsules (solid line), showing a lower relapse proportion for the duloxetine group across the timeline up to 300 days.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph depicting the percentage of patients improved on the y-axis versus the percent improvement in pain from baseline on the x-axis. It compares four groups: DUL 60mg BID, DUL 60mg QD, DUL 20mg QD, and placebo, showing trends of pain improvement across different doses of Duloxetine Delayed-Release and placebo.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60mg BID, Duloxetine 60mg QD, and placebo. Both Duloxetine groups show higher percentages of improvement compared to placebo across various levels of pain improvement.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, showing patient response trends across increasing pain improvement percentages.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Duloxetine (DUL) 120 mg once daily, 60 mg once daily, 20 mg once daily, and placebo. The y-axis shows the percentage of patients improved from 0 to 100%, and the x-axis shows increasing percentages of improvement in pain, with lines indicating dose-response trends.*

FDA Label Image

Figure 8 (Duloxetine 08)

A line chart comparing the percentage of patients improved by percent improvement in pain from baseline (BOCF) for Duloxetine Delayed-Release 60/120 mg once daily versus placebo. The graph has percent improvement on the x-axis (0 to 100) and percentage of patients improved on the y-axis (0 to 100), showing higher improvement for Duloxetine compared to placebo across most ranges.*

FDA Label Image

Figure 9 (Duloxetine 09)

A line graph comparing the percentage of patients improved over percent improvement in pain from baseline (BOCF) between placebo and Duloxetine Delayed-Release 60 mg once daily. The graph shows a declining trend in patient improvement as pain improvement percentage increases, with Duloxetine generally outperforming placebo at most points.*

FDA Label Image

Figure 10 (Duloxetine 10)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares two groups: placebo and Duloxetine Delayed-Release 60/120 mg once daily, with Duloxetine showing consistently higher patient improvement across various pain improvement thresholds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.